Clinical translation of predictive markers for anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer

Antibody Therapy ◽

Predictive Markers ◽

Clinical Translation ◽

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

British Journal of Cancer ◽

10.1038/bjc.2015.173 ◽

2015 ◽

Vol 112 (12) ◽

pp. 1888-1894 ◽

Cited By ~ 166

Author(s):

A Rowland ◽

M M Dias ◽

M D Wiese ◽

G Kichenadasse ◽

R A McKinnon ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Braf Mutation ◽

Meta Analysis ◽

Antibody Therapy ◽

Predictive Biomarker ◽

Wild Type

Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’

British Journal of Cancer ◽

10.1038/bjc.2015.325 ◽

2015 ◽

Vol 113 (11) ◽

pp. 1635-1635 ◽

Cited By ~ 5

Author(s):

Andrew Rowland ◽

Mafalda M Dias ◽

Michael D Wiese ◽

Ganessan Kichenadasse ◽

Ross A McKinnon ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Braf Mutation ◽

Meta Analysis ◽

Antibody Therapy ◽

Predictive Biomarker ◽

Wild Type

Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.3633 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 3633-3633

Author(s):

Michael Sangmin Lee ◽

Michael J. Overman ◽

Dipen M. Maru ◽

Zhi-Qin Jiang ◽

Shanequa Manuel ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Cpg Island ◽

Antibody Therapy ◽

Progression Free Survival ◽

Cpg Island Methylator Phenotype ◽

Free Survival ◽

Methylator Phenotype

PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-013-1400-x ◽

2013 ◽

Vol 139 (5) ◽

pp. 891-900 ◽

Cited By ~ 22

Author(s):

Shuangjie Wu ◽

Yu Gan ◽

Xinhai Wang ◽

Jun Liu ◽

Mengjun Li ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Meta Analysis ◽

Pik3ca Mutation ◽

Antibody Therapy ◽

Poor Survival

Biomarkers predicting clinical response to EGFR-targeted monoclonal antibody therapy in patients with metastatic colorectal cancer

World Chinese Journal of Digestology ◽

10.11569/wcjd.v18.i36.3831 ◽

2010 ◽

Vol 18 (36) ◽

pp. 3831

Author(s):

Min Shi ◽

Jun Zhang ◽

Zheng-Gang Zhu

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Clinical Response ◽

Antibody Therapy ◽

459P Effect of RAS amplification (RASa) on outcomes to EGFR monoclonal antibody therapy (EGFRmAb) in metastatic colorectal cancer (mCRC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.570 ◽

2020 ◽

Vol 31 ◽

pp. S437

Author(s):

M. Fakih ◽

J. Lee ◽

J.S. Sandhu ◽

R. Madison ◽

J. Venstrom ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Antibody Therapy ◽

Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours

European Journal of Cancer ◽

10.1016/j.ejca.2015.11.025 ◽

2016 ◽

Vol 55 ◽

pp. 122-130 ◽

Cited By ~ 17

Author(s):

Andrew Rowland ◽

Mafalda M. Dias ◽

Michael D. Wiese ◽

Ganessan Kichenadasse ◽

Ross A. McKinnon ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Meta Analysis ◽

Antibody Therapy ◽

Cost-effectiveness analysis of the use of comprehensive molecular profiling before initiating monoclonal antibody therapy against metastatic colorectal cancer in Japan

Journal of Cancer Policy ◽

10.1016/j.jcpo.2017.03.008 ◽

2017 ◽

Vol 12 ◽

pp. 61-66 ◽

Cited By ~ 6

Author(s):

Shota Saito ◽

Hitoshi Kameyama ◽

Yusuke Muneoka ◽

Shujiro Okuda ◽

Toshifumi Wakai ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Cost Effectiveness ◽

Antibody Therapy ◽

Molecular Profiling ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis

Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy

Journal of Hepatology ◽

10.1016/j.jhep.2010.04.023 ◽

2010 ◽

Vol 53 (4) ◽

pp. 677-685 ◽

Cited By ~ 31

Author(s):

Gerben J. van der Bij ◽

Marijn Bögels ◽

Marielle A. Otten ◽

Steven J. Oosterling ◽

Peter J. Kuppen ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Liver Metastases ◽

Antibody Therapy ◽

Mononuclear Phagocyte ◽

Experimentally Induced

Abstract 1734: MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies forKRASmutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy

10.1158/1538-7445.am2011-1734 ◽

2011 ◽

Author(s):

Juyong Yoon ◽

Kyoung-Hwa Koo ◽

Kang-Yell Choi

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibody ◽

Antibody Therapy ◽